Last Updated: June 2026
Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Rakib Uddin Ahmed, MBBS, MD (Hematology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from the FDA, EMA, and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: revlimid.com, drugs.com, accessdata.fda.gov, accessdata.fda.gov
Key Takeaways
Lenalidomide (available as Revlixen, Ledomide, Linamide, and Mylomid) is an immunomodulatory agent and thalidomide analogue — it is not a classical cytotoxic chemotherapy drug, as it works primarily through immune modulation rather than direct DNA damage.
It is approved for multiple myeloma (in combination with dexamethasone), maintenance therapy after autologous stem cell transplantation, myelodysplastic syndromes with deletion 5q, mantle cell lymphoma, and follicular lymphoma and marginal zone lymphoma (both in combination with rituximab).
Lenalidomide carries serious risks including embryo-fetal toxicity, hematologic toxicity (neutropenia and thrombocytopenia), and venous thromboembolism — all highlighted in the drug’s FDA boxed warnings and requiring close medical supervision.
All prescribers, pharmacists, and patients must be registered in the REMS program before lenalidomide is prescribed, dispensed, or received, and no more than a 28-day supply may be dispensed at one time.
We supply only Bangladeshi-manufactured brands (Revlixen, Ledomide, Linamide, Mylomid), available as capsules in six strengths, exclusively to hospitals, oncology centers, distributors, and institutional procurement teams in Saudi Arabia and the Middle East.
Institutions importing lenalidomide into Saudi Arabia must verify SFDA registration status and prepare full compliance documentation, including REMS compliance records, certificates of origin, and valid pharmaceutical licenses.
What Is Lenalidomide and How Does It Work?
Lenalidomide is an immunomodulatory agent belonging to the class of thalidomide analogues. It is classified among anti-neoplastic medicines with a combined mechanism of action, bringing together immunomodulatory properties, antiangiogenic activity, and anti-neoplastic activity.
In terms of mechanism of action, lenalidomide enhances T-cell proliferation and activates natural killer (NK) cells, strengthening the immune response against cancer cells. It also inhibits the formation of the new blood vessels that feed tumors, and induces apoptosis (programmed cell death) in malignant cells.
From a classification standpoint, lenalidomide is not considered a cytotoxic agent in the classical sense of conventional chemotherapy; it performs its function primarily through immunomodulatory pathways rather than through direct DNA damage. This is what makes it a distinctive therapeutic tool in the management of multiple myeloma and other hematologic malignancies, where lenalidomide 10 mg, lenalidomide 25 mg, and other strengths are used according to the clinical situation.
Approved Indications: Conditions Treated with Lenalidomide
Lenalidomide has a broad spectrum of approved therapeutic indications, the most prominent of which are set out below:
-
Multiple Myeloma:
Lenalidomide is used in combination with dexamethasone in the treatment of multiple myeloma, and this is one of the principal indications for the drug.
-
Maintenance therapy after autologous stem cell transplantation:
Lenalidomide is prescribed as maintenance therapy following autologous hematopoietic stem cell transplantation. -
Myelodysplastic Syndromes (MDS):
It is approved in cases of myelodysplastic syndromes associated with the cytogenetic abnormality of deletion of the long arm of chromosome 5 (deletion 5q). - Mantle Cell Lymphoma.
- Follicular Lymphoma.
- Marginal Zone Lymphoma.
Clinical warning: It should be noted that lenalidomide is not used in the treatment of chronic lymphocytic leukemia except within the framework of controlled clinical trials. Consultation with the treating physician is recommended to determine the suitability of this medicine for each individual case.
Available Brands: Revlixen, Ledomide, Linamide, and Mylomid
We are specialist pharmaceutical suppliers dealing exclusively in lenalidomide capsules manufactured in Bangladesh. We offer four approved brands:
-
Revlixen —
(Everest Pharmaceuticals Ltd., Bangladesh)
: one of the leading brands of generic lenalidomide. -
Ledomide —
(Renata PLC, Bangladesh)
: supplies lenalidomide capsules in multiple strengths. -
Linamide —
(Beacon Pharmaceuticals PLC, Bangladesh)
: a trusted option for oncology centers and hospitals. -
Mylomid —
(Drug International Ltd., Bangladesh)
: offers a range of strengths to meet varying patient needs.
These brands are available as capsules in the following strengths: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. This wide range of strengths covers the varied dosing requirements determined by the treating physician.
To enquire about current availability and pricing, please contact us directly. We do not offer brands originating outside Bangladesh and we do not deal in products manufactured in other countries.
Safety Profile and Risk Awareness for Lenalidomide
Lenalidomide has a safety profile that requires close monitoring by a specialist medical team. The most notable documented adverse effects are set out below:
Common Side Effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Diarrhea
- Nausea
- Peripheral Neuropathy
Serious Side Effects
-
Embryo-Fetal Toxicity:
Lenalidomide causes extremely serious birth defects. It is an analogue of thalidomide, whose severe human embryo-fetal toxicity is well established. Studies in monkeys have demonstrated limb malformations. -
Hematologic Toxicity:
Requires periodic monitoring of the complete blood count. -
Venous and Arterial Thromboembolism:
Including deep vein thrombosis (DVT) and pulmonary embolism.
Special Considerations
The safety and efficacy of lenalidomide have not been established in children, and its use is therefore not recommended in this age group. In addition, the quantity of medicine dispensed at any one time must not exceed a 28-day supply, in accordance with the requirements of the REMS program. All clinical decisions relating to dosing and the management of adverse effects are made by the treating physician on the basis of the official prescribing information.
REMS Program Requirements: What Prescribers and Pharmacists Must Know
Lenalidomide is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because of its exceptionally serious embryo-fetal toxicity. This program is a fundamental regulatory pillar with which all parties involved must comply before any handling of the medicine.
Registration Obligations
Prescribing physicians, pharmacists, and patients must be registered in the lenalidomide REMS program before the medicine is prescribed, dispensed, or received. The medicine may not be dispensed to any patient who has not satisfied the registration requirements.
Pregnancy and Lactation Restrictions
The use of lenalidomide during pregnancy is absolutely prohibited, as it causes extremely serious birth defects. The program requires strict pregnancy prevention measures to be applied in women of childbearing potential, and breastfeeding is prohibited while receiving treatment.
Dispensing Limits
No more than a 28-day supply of lenalidomide may be dispensed on a single prescription, within the mandatory framework of the REMS program. This condition is of critical importance for institutional procurement teams and for suppliers wishing to import into Saudi Arabia, as sourcing procedures must reflect these regulatory requirements.
Regulatory Context for Importing Lenalidomide into Saudi Arabia
Lenalidomide holds approval from the United States Food and Drug Administration (FDA), which constitutes an internationally recognized regulatory basis. Importing into Saudi Arabia, however, requires full compliance with the requirements of the Saudi Food and Drug Authority (SFDA).
Saudi Import Requirements
Healthcare institutions and procurement teams must verify the product’s registration status with the Saudi Food and Drug Authority (SFDA) before initiating any import procedures. Lenalidomide capsules are subject to controlled-substance requirements owing to the REMS program, which entails additional documentation at the point of import.
Required Documentation
The core documentation typically required includes: REMS compliance documentation, certificates of origin, and valid pharmaceutical licenses, together with any specific requirements for controlled substances under the applicable Saudi regulations.
Institutional buyers are advised to coordinate with their legal and regulatory advisors to verify the product’s current registration status with the SFDA and to confirm that all local requirements have been met before completing any purchase.
How to Source Lenalidomide Capsules: B2B Inquiry Process
We are specialist pharmaceutical suppliers serving hospitals, oncology centers, distributors, and procurement teams in Saudi Arabia and across the Middle East. We supply exclusively the approved Bangladeshi brands: Revlixen, Ledomide, Linamide, and Mylomid.
Inquiry Steps
-
Hospitals and oncology centers:
Contact us directly to specify the strengths and quantities required. -
Distributors and intermediaries:
We welcome long-term partnerships and provide a reliable, sustainable supply chain. -
Institutional procurement teams:
We provide full support with the required documentation and import procedures.
What We Address Upon Inquiry
We answer all questions relating to minimum order quantities (MOQ), documentation requirements, supply chain reliability, and delivery schedules. To enquire about current availability and pricing, contact us now through the communication channels available on the website.
We are committed to supplying only generic lenalidomide products manufactured in Bangladesh, and we do not deal with brands from any other source, which ensures consistency and quality in every shipment.
Side Effects of Lenalidomide
Lenalidomide is associated with a range of side effects that require monitoring by a qualified healthcare professional. The following reactions have been documented in clinical use:
- Neutropenia — reduction in neutrophil count, increasing infection risk
- Thrombocytopenia — low platelet count, which may increase bleeding risk
- Anemia — reduced red blood cell count causing fatigue and weakness
- Fatigue — persistent tiredness commonly reported during treatment
- Constipation — gastrointestinal slowing frequently observed
- Diarrhea — loose stools reported in a significant proportion of patients
- Nausea — feeling of sickness, particularly early in treatment
- Peripheral Neuropathy — numbness, tingling, or pain in the hands and feet
This list is not exhaustive. Patients should report any new or worsening symptoms to their treating physician promptly. All side effect management decisions must be made by a qualified medical professional.
Frequently Asked Questions
What type of drug is lenalidomide?
Lenalidomide is an immunomodulatory agent and a thalidomide analogue, classified as an anti-neoplastic drug with combined mechanisms including immune modulation, antiangiogenic activity, and induction of programmed cell death in malignant cells. It is not a traditional chemotherapy agent in the classical cytotoxic sense. It is used primarily in the treatment of multiple myeloma and several other hematologic malignancies.
Is lenalidomide chemotherapy or immunotherapy?
Lenalidomide is neither classical chemotherapy nor a conventional immunotherapy — it is an immunomodulatory agent that works by enhancing T-cell and natural killer cell activity, inhibiting new blood vessel formation that feeds tumors, and promoting apoptosis in cancer cells. Because it does not directly damage DNA the way traditional cytotoxic chemotherapy does, it occupies a distinct therapeutic category. Your treating physician can clarify how it fits into your specific treatment plan.
Is lenalidomide a cytotoxic drug?
No, lenalidomide is not considered a cytotoxic drug in the classical sense. Unlike conventional chemotherapy agents that act by directly damaging DNA, lenalidomide exerts its anti-tumor effects primarily through immunomodulatory and antiangiogenic pathways. This distinction makes it a unique therapeutic tool in managing multiple myeloma and related hematologic conditions.
What are the serious side effects of lenalidomide I should be aware of?
The most serious side effects documented for lenalidomide include embryo-fetal toxicity (which can cause severe birth defects), hematologic toxicity such as neutropenia, thrombocytopenia, and anemia, as well as venous and arterial thromboembolism including deep vein thrombosis and pulmonary embolism. Common side effects also include fatigue, peripheral neuropathy, nausea, and gastrointestinal disturbances. All side effects must be monitored and managed by your treating physician.
Can your company supply lenalidomide brands to hospitals and oncology centers in Saudi Arabia?
Yes, we supply the Bangladeshi-manufactured brands Revlixen, Ledomide, Linamide, and Mylomid to hospitals, oncology centers, distributors, and institutional procurement teams in Saudi Arabia and across the Middle East. We provide full support regarding required documentation and import procedures. Please contact us directly to discuss availability, quantities, and supply chain details.
What documentation is needed to import lenalidomide into Saudi Arabia?
Importing lenalidomide into Saudi Arabia typically requires verification of the product’s registration status with the Saudi Food and Drug Authority (SFDA), REMS compliance documentation, certificates of origin, and valid pharmaceutical licenses, along with any additional requirements for controlled substances under applicable Saudi regulations. We recommend coordinating with your legal and regulatory advisors before finalizing procurement. Our team can assist institutional buyers with the documentation support needed throughout the process.
Access This Medicine Through Saif Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in June 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.